azacitidine has been researched along with Granulocytic Leukemia, Chronic in 57 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (15.79) | 18.2507 |
| 2000's | 15 (26.32) | 29.6817 |
| 2010's | 28 (49.12) | 24.3611 |
| 2020's | 5 (8.77) | 2.80 |
| Authors | Studies |
|---|---|
| Amdouni, H; Auberger, P; Benhida, R; Bougrin, K; Driowya, M; Dubois, A; Dufies, M; Furstoss, N; Lacas-Gervais, S; Martin, AR; Métier, C; Orange, F; Robert, G; Zerhouni, M | 1 |
| Abdel-Wahab, O; Bhagat, TD; Boultwood, J; Dolatshad, H; Gavathiotis, E; Giricz, O; Gitego, N; Gordon-Mitchell, S; Inoue, D; Kazemi, M; Lee, J; Lopez, A; Maqbool, SB; Olea, R; Pellagatti, A; Pena, BR; Pradhan, K; Rahmani, NE; Ramachandra, N; Rao, K; Sahu, S; Shastri, A; Singh, S; Steidl, U; Sun, T; Tatwavedi, D; Tittrea, V; Verma, A; Zhang, J; Zhao, Y | 1 |
| Belli, Ç; Bulan, B; Eşkazan, AE; Yılmaz, U | 1 |
| Dhangar, S; Ghatanatti, J; Mathan S, LP; Sawant, L; Shah, A; Shanmukhaiah, C; Vundinti, BR | 1 |
| Benfaremo, D; Cardinali, M; Fraticelli, P; Gabrielli, A | 1 |
| Alvarado, Y; Demakos, EP; Fruchtman, SM; Garcia-Manero, G; John, RB; Maniar, M; Navada, SC; OdchimarReissig, R; Ohanian, MN; Pemmaraju, N; Silverman, LR; Woodman, RC; Zbyszewski, PS | 1 |
| Gangat, N; Tefferi, A | 1 |
| Guo, H; Li, XX; Lin, J; Ma, JC; Qian, J; Wen, XM; Yan, Y; Yang, L; Zhang, TJ; Zhang, W; Zhou, JD | 1 |
| Egle, A; Grabmer, C; Greil, R; Jungbauer, C; Leisch, M; Lindlbauer, N; Pleyer, L; Rohde, E; Weiss, L | 1 |
| Amarante-Mendes, GP; Calle, Y; Castro, FA; De Carvalho, DD; Hamerschlak, N; Jacysyn, JF; Jones, GE; Pagnano, KB; Pereira, WO; Ribeiro, BF; Sardinha, LR; Zanichelli, MA; Zenteno, ME | 1 |
| Bug, G; Lang, F; Ottmann, OG; Pfeifer, H; Schnittger, S; Wunderle, L | 1 |
| Al-Jamal, HAN; Ismail, I; Johan, MF; Mat Jusoh, SA; Wan Taib, WR | 1 |
| Al-Kali, A; Binder, M; Carr, R; Coston, T; Finke, CM; Gangat, N; Ketterling, RP; Lasho, TL; Litzow, M; Mangaonkar, AA; Pardanani, A; Patnaik, MM; Pophali, P; Tefferi, A; Vallapureddy, R; Zblewski, D | 1 |
| Auger, N; Bennaceur-Griscelli, A; Bourhis, JH; Castaigne, S; de Botton, S; Ghez, D; Ianotto, JC; Micol, JB; Pasquier, F; Rigaudeau, S; Rousselot, P; Saada, V; Spentchian, M; Terré, C | 1 |
| Ikezoe, T; Nishioka, C; Nobumoto, A; Tsuda, M; Yang, J; Yokoyama, A | 1 |
| Dicato, M; Diederich, M; Gaigneaux, A; Ghelfi, J; Grandjenette, C; Henry, E; Karius, T; Schnekenburger, M | 1 |
| Abdelhay, E; Binato, R; Cappelletti, P; Corrêa, S; Du Rocher, B; Ferreira, G; Mencalha, A; Pinto, LF; Soares-Lima, S | 1 |
| Gang, L; Guangxin, C; Xianjun, L; Xishan, Z; Ziying, L | 1 |
| Amabile, G; Bock, C; Brummelkamp, T; Di Ruscio, A; Ebralidze, AK; Figueroa, ME; Le Beau, MM; Levantini, E; Martinelli, G; Müller, F; Qi, L; Tenen, DG; Welner, RS; Yang, H; Zhang, H | 1 |
| Chen, Q; Guo, H; Lin, J; Qian, J; Wen, XM; Yang, J; Yang, L; Yao, DM; Zhang, YY; Zhou, JD | 1 |
| Aouba, A; Arlet, JB; Berthier, S; Braun, T; Buchdahl, AL; Decaux, O; Denis, G; Fain, O; Fenaux, P; Fraison, JB; Gardin, C; Grignano, E; Kahn, JE; Leon, N; Liozon, E; Lortholary, O; Maigne, G; Mekinian, A; Omouri, M; Park, S; Rossignol, J | 1 |
| Brown, YD; Cortes, JE; Kantarjian, HM; Maiti, A | 1 |
| Bueno, MJ; Calin, GA; Cigudosa, JC; Croce, CM; Fernández-Piqueras, J; Gómez de Cedrón, M; Malumbres, M; Pérez de Castro, I; Santos, J | 1 |
| Agirre, X; Arqueros, V; Cervantes, F; Cordeu, L; Fresquet, V; Gárate, L; Heiniger, A; Jiménez-Velasco, A; Martín, V; Martínez-Climent, JA; Prósper, F; Roman-Gomez, J; San José-Eneriz, E; Torres, A | 1 |
| Chen, YH; Gong, FJ; Kuang, WY; Li, RJ; Lu, QJ; Zhang, GS; Zhu, JF | 1 |
| Eckschlager, T; Hrabeta, J; Hrebackova, J | 1 |
| Akbulak, R; Atanackovic, D; Bartels, BM; Bartels, K; Bokemeyer, C; Brümmendorf, TH; Cao, Y; Gontarewicz, A; Gordic, M; Hildebrandt, Y; Kobold, S; Kröger, N; Lajmi, N; Luetkens, T; Meyer, S; Schafhausen, P; Stasche, T; Uhlich, F | 1 |
| Dicato, M; Diederich, M; Foliguet, B; Ghelfi, J; Grandjenette, C; Karius, T; Schnekenburger, M | 1 |
| Brodská, B; Holoubek, A; Otevřelová, P | 1 |
| Cogle, C; Garcia-Manero, G; Giordano, H; Gore, SD; Jabbour, E; Kantarjian, H; Laille, E; Macbeth, KJ; Sakoian, S; Shi, T; Skikne, B; Ward, R | 1 |
| Chan, KW; Lockhart, S; McDonald, L; Rytting, M | 1 |
| Cui, XY; Gao, WF; Lin, YM; Ma, XT; Wang, N; Yang, BX; Yao, XR | 1 |
| Fan, RF; Fang, ZG; Lin, DJ; Liu, XF; Long, ZJ; Lu, Y; Zhai, FX; Zheng, YJ | 1 |
| Chen, JB; Li, Y; Liu, Q; Ren, GS; Song, JJ; Xiang, TX; Yang, L; Yang, ZS | 1 |
| Bowen, DT; Durairaj, S; Groves, MJ; Hyslop, A; Keenan, N; Tauro, S | 1 |
| Chang, JG; Lin, PM; Lin, SF; Liu, TC; Yang, MY | 1 |
| Andreeff, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Issa, JP; Kantarjian, HM; Keating, M; O'Brien, S; Rios, MB; Shan, J; Talpaz, M | 1 |
| Corbin, AS; Deininger, MW; Druker, BJ; Johnson, K; La Rosée, P; Mauro, MM; Melo, JV; Moseson, EM; Stoffregen, EP; Willis, S | 1 |
| Dörken, B; Schmelz, K; Tamm, I; Wagner, M | 1 |
| Cortes, J; Garcia-Manero, G; Gharibyan, V; Issa, JP; Jelinek, J; Kantarjian, HM; Morris, G; Talpaz, M; Verstovsek, S | 1 |
| Byrd, JC; Issa, JP | 1 |
| Choi, SW; Doshi, KD; Estecio, MR; Garcia-Manero, G; Gharybian, V; Issa, JP; Kantarjian, HM; Luna, R; Mannari, RK; Mason, JB; Rashid, A; Shen, L; Yang, AS | 1 |
| Cortes, J; Kantarjian, HM | 1 |
| Pu, Q | 1 |
| Chang, JG; Chen, YH; Hsiao, HH; Lin, HY; Lin, PM; Lin, SF; Liu, TC; Liu, YC; Tang, KP; Yang, MY | 1 |
| Galili, N; Raza, A; Raza, FZ | 1 |
| Endo, T; Fukumaki, Y; Ishibashi, Y; Okano, H; Shiokawa, S | 1 |
| Bennett, J; Browman, G; Bryant, J; Goldberg, J; Grunwald, H; Gryn, J; Larson, R; Preisler, H; Raza, A; Vogler, R | 1 |
| Catapano, CV; Colombo, T; Conter, V; Damia, G; Gervasoni, M; Giudici, G; Limonta, M; Liso, V; Masera, G; Specchia, G | 1 |
| Champlin, R; Davis, M; de Vos, D; Giralt, S; Kantarjian, H; O'Brien, S; van Besien, K | 1 |
| Beran, M; de Vos, D; Estey, E; Giralt, S; Kantarjian, HM; Keating, M; O'Brien, SM; Rios, MB; Talpaz, M | 1 |
| Beran, M; de Vos, D; Estey, E; Giralt, S; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, SM; Rios, MB; Talpaz, M | 1 |
| Estey, E; Kantarjian, HM; Keating, MJ; O'Brien, S; Plunkett, W; Rios, MB; Sorenson, M; Wilhelm, M | 1 |
| Beran, M; Cortes, J; Giles, FJ; Kantarjian, HM; Keating, MJ; Koller, CA; O'Brien, S; Rios, MB; Sacchi, S; Talpaz, M | 1 |
| Arlin, Z; Bennett, JM; Dutcher, JP; Eudey, L; Kellermeyer, R; O'Connell, M; Oken, M; Paietta, E; Rowe, J; Wiernik, PH | 1 |
6 review(s) available for azacitidine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review.
Topics: Azacitidine; Gemtuzumab; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors | 2022 |
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Decitabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Sulfonamides | 2020 |
Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options.
Topics: Adult; Azacitidine; Dasatinib; Drug Therapy, Combination; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Stem Cell Transplantation | 2017 |
Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Topics: Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2005 |
Decitabine in chronic leukemias.
Topics: Azacitidine; Chronic Disease; Combined Modality Therapy; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2005 |
New strategies in chronic myeloid leukemia.
Topics: Angiogenesis Inhibitors; Azacitidine; Benzamides; Cancer Vaccines; Clinical Trials as Topic; Decitabine; Drug Resistance, Neoplasm; Farnesyl-Diphosphate Farnesyltransferase; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors | 2006 |
12 trial(s) available for azacitidine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Glycine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Sulfones | 2020 |
Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Decitabine; Disease-Free Survival; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Survival Rate; Time Factors | 2019 |
Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Azacitidine; Biomarkers; Bone Marrow; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Protein Kinase Inhibitors; Treatment Outcome | 2017 |
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites; Antimetabolites, Antineoplastic; Azacitidine; Biological Availability; DNA Methylation; Fatigue; Female; Gastrointestinal Diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neutropenia | 2011 |
Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies | 2013 |
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Benzamides; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study.
Topics: Adult; Azacitidine; Biopsy; Blast Crisis; Bone Marrow; Cell Cycle; DNA, Neoplasm; Female; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Outcome Assessment, Health Care; Recurrence | 1993 |
Studies of decitabine with allogeneic progenitor cell transplantation.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Decitabine; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Patient Selection; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pseudomonas Infections; Recurrence; Time Factors; Transplantation, Homologous | 1997 |
Decitabine studies in chronic and acute myelogenous leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Female; Fever; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged | 1997 |
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Decitabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged | 1997 |
Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Blast Crisis; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Salvage Therapy; Treatment Outcome | 1999 |
Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Drug Evaluation; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Mitoxantrone; Remission Induction | 1992 |
39 other study(ies) available for azacitidine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
In Vitro and in Vivo Evaluation of Fully Substituted (5-(3-Ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as Original Nucleoside Analogues to Circumvent Resistance in Myeloid Malignancies.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Glycosides; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Mice, Nude; Myelodysplastic Syndromes; Triazoles; Tumor Cells, Cultured | 2017 |
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.
Topics: Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Point Mutation; Repressor Proteins; Sulfonamides | 2021 |
Synergetic effect of Azacitidine and Sorafenib in treatment of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement.
Topics: Azacitidine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Receptor, Fibroblast Growth Factor, Type 1; Sorafenib; Translocation, Genetic | 2023 |
Atypical neutrophilic panniculitis as presentation of BCR-ABL1-negative chronic myeloid leukaemia.
Topics: Administration, Intravenous; Adrenal Cortex Hormones; Azacitidine; Diagnosis, Differential; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutrophils; Panniculitis; Skin Neoplasms; Skin Ulcer; Treatment Outcome | 2019 |
Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Case-Control Studies; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; HL-60 Cells; Humans; Inhibitor of Differentiation Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Signal Transduction; Survival Analysis | 2017 |
Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Erythrocyte Transfusion; Erythrocytes; Female; Humans; Isoantibodies; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transfusion Reaction | 2017 |
BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Carcinogenesis; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Promoter Regions, Genetic; Protein Kinase Inhibitors; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Wiskott-Aldrich Syndrome Protein | 2017 |
Re-Expression of Bone Marrow Proteoglycan-2 by 5-Azacytidine is associated with STAT3 Inactivation and Sensitivity\
Response to Imatinib in Resistant CML Cells
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Azacitidine; Bone Marrow; Cell Proliferation; Drug Resistance, Neoplasm; Eosinophil Major Basic Protein; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Proteoglycans; STAT3 Transcription Factor; Tumor Cells, Cultured | 2018 |
Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Survival; Dasatinib; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
5-aza-2'-deoxycytidine-mediated c-myc Down-regulation triggers telomere-dependent senescence by regulating human telomerase reverse transcriptase in chronic myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Cycle Proteins; Cell Line, Tumor; Cellular Senescence; Decitabine; DNA Damage; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-myc; Telomerase; Telomere Shortening; Transcription, Genetic | 2014 |
ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.
Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Azacitidine; Benzamides; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Piperazines; Promoter Regions, Genetic; Pyrimidines | 2014 |
The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia.
Topics: 3' Untranslated Regions; Adolescent; Adult; Aged; Azacitidine; Bone Marrow; Bone Marrow Cells; Cell Line, Tumor; Cellular Senescence; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Matrix Metalloproteinase 9; MicroRNAs; Middle Aged; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; Young Adult | 2014 |
Dissecting the role of aberrant DNA methylation in human leukaemia.
Topics: Animals; Azacitidine; Cell Differentiation; Cellular Reprogramming Techniques; DNA Methylation; Genes, abl; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, Transgenic; U937 Cells | 2015 |
GPX3 promoter is methylated in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Case-Control Studies; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutathione Peroxidase; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Staging; Promoter Regions, Genetic; RNA, Messenger; Young Adult | 2015 |
Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azacitidine; Female; Humans; Inflammation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies | 2016 |
Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression.
Topics: 3' Untranslated Regions; Animals; Azacitidine; Cell Line, Tumor; Cell Proliferation; Chromosomes, Human, Pair 14; Chromosomes, Mammalian; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Loss of Heterozygosity; Lymphoma, T-Cell; Lymphoproliferative Disorders; Mice; Mice, Inbred C57BL; MicroRNAs; Phenylbutyrates; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; Proto-Oncogene Proteins c-abl; Time Factors; Transfection; Up-Regulation; Whole-Body Irradiation | 2008 |
Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Bcl-2-Like Protein 11; Benzamides; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Membrane Proteins; Middle Aged; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Proteins; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 2009 |
Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Base Sequence; Blotting, Western; DNA Methylation; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Flow Cytometry; Gene Expression Regulation, Enzymologic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondrial Proton-Translocating ATPases; Molecular Sequence Data; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2010 |
Valproic acid in the complex therapy of malignant tumors.
Topics: Acetylation; Angiogenesis Inhibitors; Apoptosis; Azacitidine; Cell Cycle; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; Drug Repositioning; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Epilepsy; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Topoisomerase II Inhibitors; Tumor Suppressor Protein p53; Valproic Acid | 2010 |
Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Benzamides; Decitabine; Disease-Free Survival; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Immunity, Humoral; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines | 2010 |
Sustained exposure to the DNA demethylating agent, 2'-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy.
Topics: Aging; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Azacitidine; Cell Differentiation; Cell Line, Tumor; Cell Survival; Decitabine; DNA Methylation; Drug Synergism; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2011 |
Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cells, Cultured; Decitabine; Drug Evaluation, Preclinical; Drug Synergism; Gene Expression Regulation, Leukemic; Humans; Hydroxamic Acids; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Up-Regulation; Vorinostat | 2011 |
Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ ALL resolution after decitabine therapy.
Topics: Azacitidine; Benzamides; Child, Preschool; Chromosome Aberrations; Decitabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation | 2012 |
HSPB8 is methylated in hematopoietic malignancies and overexpression of HSPB8 exhibits antileukemia effect.
Topics: Azacitidine; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Hematologic Neoplasms; HL-60 Cells; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma; Molecular Chaperones; Protein Serine-Threonine Kinases; Tumor Cells, Cultured | 2012 |
RUNX3 is involved in caspase-3-dependent apoptosis induced by a combination of 5-aza-CdR and TSA in leukaemia cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Proliferation; Core Binding Factor Alpha 3 Subunit; CpG Islands; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation | 2012 |
Epigenetic inactivation of PLCD1 in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Biomarkers, Tumor; Bone Marrow Cells; CpG Islands; Decitabine; DNA Methylation; Female; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phospholipase C delta; Promoter Regions, Genetic; RNA, Messenger; Tumor Suppressor Proteins; Young Adult | 2012 |
Decitabine has promising clinical activity in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials, Phase I as Topic; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Failure | 2002 |
JunB gene expression is inactivated by methylation in chronic myeloid leukemia.
Topics: Azacitidine; Computer Systems; CpG Islands; Decitabine; DNA Methylation; DNA Mutational Analysis; DNA, Complementary; DNA, Neoplasm; Gene Expression Regulation, Leukemic; Genes, jun; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Promoter Regions, Genetic; Proto-Oncogene Proteins c-jun; Reverse Transcriptase Polymerase Chain Reaction | 2003 |
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Decitabine; DNA Modification Methylases; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged | 2003 |
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Azacitidine; Base Sequence; Benzamides; Cell Division; Cell Line, Tumor; Decitabine; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.
Topics: Apoptosis; Azacitidine; Blotting, Western; Caspase 3; Caspases; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; CpG Islands; Cyclin-Dependent Kinase Inhibitor p21; Cytochromes c; Decitabine; DNA Methylation; DNA-Binding Proteins; Epithelial Cells; Flow Cytometry; G1 Phase; Genes, Tumor Suppressor; HeLa Cells; HL-60 Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Membrane Potentials; Microscopy, Fluorescence; Mitochondria; Myelodysplastic Syndromes; Nuclear Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Sulfites; Time Factors; Transfection; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; U937 Cells; Up-Regulation | 2005 |
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Female; Genes, p53; Homeodomain Proteins; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; RNA, Long Noncoding; RNA, Untranslated | 2006 |
[Further improving the standard of treatment for chronic myeloid leukemia].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Benzamides; Cancer Vaccines; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Tumor Necrosis Factor-alpha | 2006 |
Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3.
Topics: Adult; ARNTL Transcription Factors; Azacitidine; Basic Helix-Loop-Helix Transcription Factors; Blast Crisis; Cell Cycle Proteins; Circadian Rhythm; CLOCK Proteins; Cryptochromes; DNA Methylation; Down-Regulation; Flavoproteins; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nuclear Proteins; Period Circadian Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Trans-Activators; Transcription Factors | 2006 |
Low-dose decitabine and high-risk MDS.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methylation; Myelodysplastic Syndromes; Neoplasm Proteins; Protein Processing, Post-Translational; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors | 2006 |
Differential induction of adult and fetal globin gene expression in the human CML cell subline KU-812F/33.
Topics: Azacitidine; Cell Differentiation; Daunorubicin; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Erythrocytes; Fetal Hemoglobin; Globins; Hemin; Hemoglobins; Humans; Isoelectric Focusing; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Succinates; Succinic Acid; Tumor Cells, Cultured | 1994 |
Cytotoxic activity and mechanism of action of 5-Aza-2'-deoxycytidine in human CML cells.
Topics: Antineoplastic Agents; Azacitidine; Blast Crisis; Cytarabine; Decitabine; DNA, Neoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Time Factors; Tumor Cells, Cultured | 1993 |
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Decitabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Remission Induction; Salvage Therapy; Survival Analysis | 1999 |